Takashi Kojima, Takashi Ogata, Ryu Ishihara, Hiroki Hara, Tianmo Sun, Sheng Xu, Ken Kato. "First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.420